Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keros Therapeutics, Inc.KROS · Entity 6242 | Chief Scientific Officer | July 15, 2022 | July 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keros Therapeutics, Inc.
Report date July 15, 2022 · Filed July 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,100 |
Ending reported balance
After 2022-07-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-07-15 · Exercise / conversion · Acquired 46,034 · Balance 141,134 Row 2 · 2022-07-15 · Sale · Disposed 46,034 · Balance 95,100 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2028-03-25 | Direct | 8,755 |
Reported balance
After 2022-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-15 · Exercise / conversion · Disposed 46,034 · Balance 8,755 F2: Immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: Immediately exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 10, 2021 Filed Jan 12, 2021 17:21 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 42,250 | $0.00 Strike: $70.93 | $0.00 |
DisclosureSEC source: 0001209191-21-003272 · doc4.xml · derivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,250 Underlying: Common Stock · 42,250 shares Expires 2031-01-09 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 7, 2022, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 21:00 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 241,222 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023988 · doc4.xml · derivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,222 Underlying: Common Stock · 241,222 shares Expires 2030-04-06 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on March 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.